(NationalFreedomPress.com) – President Trump delivers on his promise to slash prescription drug costs by securing historic agreements with nine pharmaceutical giants, forcing Big Pharma to align U.S. prices with the lowest rates paid by other developed nations.
Story Highlights
- Nine major drugmakers agree to Most Favored Nation pricing, joining five companies already committed
- GLP-1 diabetes and weight loss drugs capped at $245 monthly for Medicare patients
- Deals leverage tariff relief and trade policy to force pharmaceutical concessions
- TrumpRx platform enables direct-to-consumer discounts bypassing traditional middlemen
Trump Administration Forces Pharmaceutical Compliance
The White House announced December 19, 2025, that Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi joined Most Favored Nation agreements. These deals require companies to price select medications at levels matching the lowest costs in other wealthy countries. The agreements represent a fundamental shift from decades of pharmaceutical industry resistance to international reference pricing, demonstrating Trump’s effective use of executive leverage against corporate price manipulation.
Strategic Executive Action Delivers Results
Trump signed Executive Order 14297 on May 12, 2025, directing HHS to establish MFN price targets for Medicare and Medicaid. The administration sent letters to 17 manufacturers on July 31, outlining expectations for MFN pricing extension to Medicaid and participation in direct-distribution models. This systematic approach forced pharmaceutical companies to negotiate rather than face potential tariffs, regulatory restrictions, or loss of federal purchasing power through Medicare and Medicaid programs.
Earlier agreements with Pfizer, AstraZeneca, EMD Serono, Eli Lilly, and Novo Nordisk established the framework for December’s expanded deals. These initial negotiations demonstrated the administration’s willingness to combine trade policy with healthcare reform, using Section 232 tariff exemptions and domestic investment commitments as bargaining tools. The strategy proved effective in breaking pharmaceutical industry opposition to international price alignment.
Substantial Patient Savings Secured
Popular GLP-1 medications including Ozempic, Mounjaro, Wegovy, and Zepbound will cost Medicare patients $245 monthly across all doses and indications. EMD Serono’s IVF therapies receive approximately 84% discounts through the TrumpRx platform. These reductions address Americans’ frustration with paying significantly higher prices than patients in other countries for identical medications, correcting a system that subsidized foreign healthcare at American expense.
The TrumpRx direct-to-consumer platform enables cash-paying patients to access MFN pricing while bypassing traditional pharmacy benefit managers and wholesalers. This approach reduces administrative costs and eliminates middleman markups that previously inflated patient costs. The platform represents a market-based solution that increases price transparency and gives patients direct access to negotiated rates.
Copyright 2025, NationalFreedomPress.com
